Autoimmunity and Benefit/Risk Profile of Alemtuzumab for Multiple Sclerosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Mult. Scler. 2021 Dec 09;[EPub Ahead of Print], AJ Coles, JL Jones, P Vermersch, A Traboulsee, AD Bass, A Boster, A Chan, G Comi, Ó Fernández, G Giovannoni, E Kubala Havrdova, C LaGanke, X Montalban, C Oreja-Guevara, F Piehl, H Wiendl, T ZiemssenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.